<DOC>
	<DOC>NCT01303952</DOC>
	<brief_summary>Evaluation of the efficacy and safety of eculizumab in symptomatic or transfusion-dependent patients with untreated or refractory hemolytic cold agglutinin disease(CAD)</brief_summary>
	<brief_title>Therapy of Chronic Cold Agglutinin Disease With Eculizumab</brief_title>
	<detailed_description />
	<mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
	<mesh_term>Complement System Proteins</mesh_term>
	<mesh_term>Cold agglutinins</mesh_term>
	<mesh_term>Agglutinins</mesh_term>
	<criteria>Individuals at least 18 years of age Diagnosis of CAD defined by the combination of chronic hemolysis, cold agglutinin titer (IgM or IgA) &gt;64 at 4°C, positive direct antiglobulin test (DAT) when performed with polyspecific antiserum, negative (or only weakly positive) antiIgG, and strongly positive with antiC3d LDH level &gt; 2 x upper limit of normal (ULN) Clinical symptoms requiring treatment, such as anemia, anemiarelated symptoms or hemolysisrelated symptoms Sufficient supplementation of iron, folic acid and vitamin B12 prior to treatment phase Patient must be willing and able to give written informed consent; Patients must be vaccinated against N. meningitidis at least 14 days prior treatment Patient must avoid conception during the trial using a method that is most appropriate for their physical state and culture Active aggressive lymphoma requiring therapy or an active nonlymphatic malignant disease other than basal cell carcinoma or CIS of the cervix Liver disease with elevated LDH Absolute neutrophil count &lt; 500/µL Presence or suspicion of active bacterial or viral infection, in the opinion of the Investigator, at treatment start or severe recurrent bacterial infections Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedure within 30 days prior to screening period Pregnant, breastfeeding, or intending to conceive during the course of the study, including the Posttreatment Phase History of bone marrow/stem cell transplantation Inability to cooperate or any condition that, in the opinion of the investigator, could increase the patient's risk by participating in the study or confound the outcome of the study Hypersensitivity to eculizumab, to murine proteins or to one of the excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>cold agglutinin disease</keyword>
	<keyword>hemolysis</keyword>
	<keyword>eculizumab</keyword>
	<keyword>terminal complement inhibition</keyword>
</DOC>